Lucence, DxD Hub and NCCS launch $6 mil cancer diagnostics research collaboration

Nurdianah Md Nur03-13 05:11

The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.A $6 million research ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619114899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619114899","market":"other","top_or_hot":-1,"title":"Lucence, DxD Hub and NCCS launch $6 mil cancer diagnostics research collaboration","media":"Nurdianah Md Nur","content":"<div>\n<p>The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.A $6 million research ...</p>\n\n<a href=\"https://www.theedgesingapore.com/digitaledge/healthcare/lucence-dxd-hub-and-nccs-launch-6-mil-cancer-diagnostics-research?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n","source":"edge_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucence, DxD Hub and NCCS launch $6 mil cancer diagnostics research collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucence, DxD Hub and NCCS launch $6 mil cancer diagnostics research collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 05:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/digitaledge/healthcare/lucence-dxd-hub-and-nccs-launch-6-mil-cancer-diagnostics-research?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>Nurdianah Md Nur</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.A $6 million research ...</p>\n\n<a href=\"https://www.theedgesingapore.com/digitaledge/healthcare/lucence-dxd-hub-and-nccs-launch-6-mil-cancer-diagnostics-research?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.theedgesingapore.com/digitaledge/healthcare/lucence-dxd-hub-and-nccs-launch-6-mil-cancer-diagnostics-research?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","article_id":"2619114899","we_media_id":null,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/digitaledge/healthcare/lucence-dxd-hub-and-nccs-launch-6-mil-cancer-diagnostics-research?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619114899","pubTimestamp":1773349873,"columns":[],"sourceInfo":{"source_id":"edge_highlight","name":"Edge"},"weMediaInfo":null,"summary":"The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.","collect":0,"end_time":0,"defaultTopTitle":"theedgesingapore.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4121":"生命科学工具和服务","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4131":"航空货运与物流","BK4109":"特种化学制品","HUBG":"Hub Group Inc","DNA":"Ginkgo Bioworks Holdings Inc.","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","RNA":"Atrium Therapeutics","BK4588":"碎股","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4505":"高瓴资本持仓"},"translate_title":"Lucence、DxD Hub和NCCS启动价值600万美元的癌症诊断研究合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"DNA":1,"HUBG":1.5},"content_text":"The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.A $6 million research collaboration to develop a next-generation clinical-grade cancer profiling test has been launched by Singapore-based precision oncology company Lucence, together with the Diagnostics Development Hub (DxD Hub), hosted by the Agency for Science, Technology and Research, and the National Cancer Centre Singapore (NCCS).\nCalled UNITED 2.0, the three-year initiative aims to advance precision diagnostics by building a more comprehensive genomic test that can help doctors match patients with targeted cancer treatments.\nThe test is being developed to support analysis across a range of tumour types, including breast, lung,  colon and bladder cancers, as well as central nervous system tumours and lymphoma.\nThe collaboration builds on the original UNITED 1.0 tissue test, also known as UNITED 600, which has helped guide therapeutic selection for cancer patients across the region since 2021. It analyses tumour tissue samples for 572 genes and 71 ribonucleic acid (RNA) fusions using both deoxyribonucleic acid (DNA) and RNA signals to identify mutations that may respond to specific therapies.\nTaking a broader approach, UNITED 2.0 will use a combination of whole exome sequencing and whole transcriptome sequencing to examine a much larger portion of the cancer genome and its expressed RNA. This will enable more detailed tumour profiling, including the identification of complex mutations and fusions, helping clinicians identify genetic alterations that can be targeted with precision treatments. \nArtificial intelligence (AI) tools will also be used to help analyse and interpret the large volumes of genomic data generated by the test, with the goal of producing clearer and faster clinical reports.\n“UNITED 2.0 moves us from a ‘snapshot’ to a high-definition map of a patient’s cancer. By integrating AI with comprehensive DNA and RNA sequencing, we are turning massive amounts of complex data into clear, actionable answers that will help clinicians choose better treatments faster,” says Dr Tan Min-Han, founding chief executive and medical director of Lucence.\nThe test is being developed to support analysis across a range of tumour types, including breast, lung, colon and bladder cancers, as well as central nervous system tumours and lymphoma.\nBeyond tumour profiling, the research programme also includes plans to develop tools that track a patient’s status after treatment. One area of focus is minimal residual disease testing, which seeks to detect very small traces of cancer that remain after therapy and may signal early recurrence.\n“Clinical diagnostics only create value when it performs reliably in real-world settings and fit into routine care. With UNITED 2.0, we are strengthening the end-to-end test design, from sample handling to analytical validation and clinical reporting, so that more comprehensive tumour profiling can move from advanced sequencing into dependable clinical use,” says Dr Weng Ruifen, chief executive of DxD Hub.\nAssistant Professor Jason Chan, director of the Cancer Discovery Hub at the NCCS, adds: \"While the earlier assay already advanced precision cancer diagnostics, this latest collaboration represents an opportunity to incorporate cutting-edge tumour sequencing technologies into the original platform, enabling even more comprehensive and in-depth tumour analysis. We hope that this will help clinicians successfully treat patients with rare cancers, or those who have exhausted standard treatment options, in the future.”\nSeparately, Lucence and DxD Hub have signed a memorandum of understanding (MOU) with the Brain Tumour Society Singapore to bring patient perspectives into the research and development process. This aims to ensure that future diagnostic tools better reflect the needs and experiences of patients.\n“A precise diagnosis is the foundation of the patient journey, but the process is often hidden from the patient. This MOU represents a formal commitment to keep the patient’s perspective at the heart of cancer research,” says Melissa Lim, president of the Brain Tumour Society Singapore.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619114899","isCrawlerRequest":true}